ClearPath Invest vs. the big dashboards.
Honest head-to-head across six common alternatives. Where competitors genuinely do something better, we say so. Pick the row that matters most to you and see who wins it.
| Capability | ClearPath Invest Free beta · $29–500/mo | Empower (Personal Capital) Free dashboard · 0.49–0.89% AUM for advisors | Morningstar Free tier · Premium ~$35/mo · Investor ~$250/yr | Seeking Alpha Free · Premium $239/yr · Pro $2,400/yr | Yahoo Finance Free · Plus ~$35/mo · Gold ~$250/mo | ChatGPT / Gemini / Claude $0–$20/mo | Stock Rover $8–$28/mo |
|---|---|---|---|---|---|---|---|
Evidence-based No vibes, no training-data summaries. | Yes | Partial | Yes | Partial | No | No | Partial |
Live data SEC, Fed, market feeds — not cached summaries. | Yes | Yes | Partial | Yes | Yes | Partial | Partial |
Multi-model Three reasoning engines, not one. | Yes | No | No | No | No | No | No |
Traces every claim Click any number → source document. | Yes | No | Partial | No | No | Partial | No |
Public track record Hit rate, losses included. | Yes | No | Partial | Partial | No | No | No |
Shows disagreement Surfaces model splits, never hides them. | Yes | No | No | Partial | No | No | No |
Portfolio sync Read-only connection to your brokerage. | Yes | Yes | Partial | Partial | Partial | No | Yes |
Defaults to HOLD When evidence is ambiguous, we say so. | Yes | No | Partial | No | No | No | No |
Best for | Retail investors who want rigor without an advisor | Net-worth aggregation + human advice | Mutual fund / ETF research and star ratings | Reading individual-investor opinions on tickers | Free quotes, charts, earnings calendars | Explaining concepts, brainstorming | Screening and backtesting with rich fundamentals |
Pricing accurate as of April 2026; always double-check each vendor’s current list price. “Partial” means the tool has something adjacent but not the same capability.
Where each competitor wins — and where we do.
ClearPath vs. Empower (Personal Capital)
Net-worth tracker + human advisor upsell. · Free dashboard · 0.49–0.89% AUM for advisors
Best-in-class net-worth aggregation across banking, real estate, and retirement accounts. Genuine fiduciary advisors available.
Empower is a dashboard + lead-gen for their advisory service. It doesn't research individual securities. We do — with cited sources.
ClearPath vs. Morningstar
Fund ratings + equity research by analysts. · Free tier · Premium ~$35/mo · Investor ~$250/yr
30+ years of analyst equity research, deep fund data, respected star ratings. Fantastic for mutual funds and ETFs specifically.
Morningstar research is human-written, slow, and fund-focused. We give you a fresh, cited multi-lens read on any US equity in minutes.
ClearPath vs. Seeking Alpha
Crowd-sourced analysis + quant ratings. · Free · Premium $239/yr · Pro $2,400/yr
Huge library of ticker-specific articles and a community that debates each thesis. Quant grades per ticker are a useful cross-check.
SA is user-generated opinion. Quality is uneven, claims are rarely sourced, and there's no consensus score. We're the opposite.
ClearPath vs. Yahoo Finance
Free financial data, charts, and news. · Free · Plus ~$35/mo · Gold ~$250/mo
Free, ubiquitous, comprehensive raw data. Best single place to glance at a chart and a news headline.
Yahoo shows you numbers; it doesn't reason about them. We translate the same data into a sourced, opinionated, auditable brief.
ClearPath vs. ChatGPT / Gemini / Claude
General-purpose chatbots. · $0–$20/mo
Best tool on earth for explaining a concept or exploring a new topic. Free or near-free.
A single chatbot hallucinates, can't reliably cite live 10-Qs, and won't flag its own disagreement. We run three model families in parallel with a supervisor that rejects unverified claims.
ClearPath vs. Stock Rover
Quant screener with historical data. · $8–$28/mo
Excellent screening, portfolio analytics, and 10-year backtesting built on a huge historical fundamentals dataset.
Stock Rover gives you fields; you still have to form the thesis. We deliver the thesis — with signals, disagreements, and sources — on top of the data.
Decide for yourself.
Request access to the private beta. Runs on live SEC, Federal Reserve, and market data. Every claim traces to its source.
Informational only · Not investment advice